Levodopa
Dopa and Dopa Derivatives
Sold as Onerji · Inbrija · Numient · DUODOPA · STALEVO
- Drug class
- Dopa and Dopa Derivatives
- Availability
- Prescription and OTC
- Routes
- Oral, Intraintestinal (Upper), Respiratory (Inhalation)
- Markets covered
- 4
- Products on record
- 126
- FDA reports (12 mo)
- 3,329
Overview
Plain-language summary, compiled from the cited regulatory records
Levodopa is an aromatic amino acid that belongs to the drug class of dopa and dopa derivatives [1]. It is approved for the intermittent treatment of "OFF" episodes in patients with Parkinson's disease who are already being treated with carbidopa/levodopa [1]. These "OFF" episodes are periods when Parkinson's disease symptoms return before the next dose of medication is due [1].
Levodopa is available under various brand names, including Inbrija [1]. In the past 12 months, there have been 3,329 adverse event reports associated with levodopa [2]. The most frequently reported adverse events include death, hallucination, fall, drug ineffective, and dyskinesia [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 93 | May 29, 2026 |
| CA Canada | Health Canada | 26 | January 19, 2026 |
| EU European Union | EMA | 5 | May 5, 2026 |
| US United States | FDA | 2 | September 22, 2025 |
GBUnited Kingdom· MHRA
93 products
Uses
For treatment of Parkinson’s disease and syndrome.
How to take
CACanada· Health Canada
26 products
Uses
AA-LEVOCARB CR (levodopa and carbidopa controlled-release tablets) is indicated for the treatment of Parkinson's disease. AA-LEVOCARB CR is not recommended for the treatment of drug-induced extrapyramidal reactions. 1 Pediatrics Pediatrics (< 18 years of age): The safety and efficacy of AA-LEVOCARB CR in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use.
2 Recommended Dose and Dosage Adjustment)
How to take
EUEuropean Union· EMA
5 products
Uses
Onerji is indicated for the treatment of motor fluctuations in patients with advanced Parkinson's disease which are not sufficiently controlled by oral anti-Parkinson medicinal products.
How to take
USUnited States· FDA
2 products
Uses
1 INDICATIONS AND USAGE INBRIJA is indicated for the intermittent treatment of OFF episodes in patients with Parkinson's disease treated with carbidopa/levodopa. INBRIJA is an aromatic amino acid indicated for the intermittent treatment of OFF episodes in patients with Parkinson's disease treated with carbidopa/levodopa ( 1 )
How to take
Drug interactions
Known interactions involving Levodopa. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 287. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL002890785 · revised January 17, 2025
- [2]Health Canada (DPD) · 02245211 · revised March 22, 2025
- [3]European Medicines Agency · EMEA/H/C/006429 · revised May 5, 2026
- [4]FDA DailyMed · 077c0f39-a3a2-4b… · revised September 22, 2025 [PDF]
- [5]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.